Here are the Fixed-dose Combination of Dapagliflozin and Linagliptin in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Randomized Double-blind Multicenter Trial journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Dapagliflozin information for patients, dapagliflozin empagliflozin equivalent dose, fixed dose combination upsc, for dapagliflozin is prescription required, what is fixed dose combination, how much does dapagliflozin cost, mirabegron/solifenacin fixed dose combination, what is fixed dose combination drug, dapagliflozin how to take.
Fixed-dose Combination of Dapagliflozin and Linagliptin in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Randomized Double-blind Multicenter Trial
Context: Combining dipeptidyl peptidase 4 inhibitors and sodium-glucose cotransporter-2 inhibitors in therapy could be beneficial for those with metformin intolerance or not achieving adequate control. Aims: To evaluate the efficacy, safety, and tolerability of a fixed-dose combination (FDC) of dapagliflozin plus linagliptin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. Settings and Design: It is a phase III, prospective, randomized, double-blind, multicenter study. Materials and
Methods: Patients with T2DM, with a stable dose of metformin ≥1000 mg/day as monotherapy for at least 3 months before screening, with inadequate glycemic control at screening were randomly assigned to either arm A (dapagliflozin 10 mg + linagliptin 5 mg) or arm B (linagliptin 5 mg) in a 1:1 ratio. Statistical Analysis Used: The primary and secondary efficacy endpoint analyses were done using repeated measures analysis of covariance or a two-sample t test. All safety parameters were analyzed using a two-sample t test and descriptive statistics.
Results: A total of 232 patients were randomized in arm A (n = 112) and arm B (n = 110). At week 16, arm A showed a significant mean reduction in glycated hemoglobin (HbA1c) than arm B (-1.35% vs. -0.92%; P≤0.0001). Similarly, the mean reductions in fasting plasma glucose (-26.13 mg/dL vs. -22.59 mg/dL; P = 0.0492), 2-h postprandial plasma glucose (-52.29 mg/dL vs. -30.35 mg/dL; P≤0.0001), and body weight (-1.32 kg vs. -0.42 kg; P≤0.0001) were significantly higher in arm A than in arm B. Arm A had a higher proportion of patients achieving HbA1c <7.0% (42.24% vs. 22.41%; P = 0.0012). Adverse events were comparable between study arms. Conclusions: The FDC of dapagliflozin and linagliptin was superior in terms of improvement in glycemic control and a higher proportion of patients achieving target HbA1c level, with both treatment arms being well-t olerated. © 2025 Journal of Diabetology.
Authors : Kumthekar P.; Upadhyay M.R.; Tamma R.R.; Kranti V.; Bhattacharya R.; Sharma P.K.; Barge V.B.; Revankar S.; Ghatge S.
Source : Wolters Kluwer Medknow Publications
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.4103/jod.jod_169_24 |
| ISSN | 25433288 |
| Volume | 16 |
You can download the article here
If You have any problem, contact us here